Posted on 20/01/2010 in Pharmaceutical Company Product News Roche revealed this week that it will invest 190 million Swiss francs (112.18 million pounds) into centres working towards the development of a device that will allow patients to self-administer biological cancer therapies.
The infusion-free product delivers Herceptin (trastuzumab), a formulation developed with Halozyme Therapeutics' Enhanze technology, to patients being treated for the disease.
This allows for the injection of larger volumes of medicines into the tissue under the skin, meaning that therapies currently administered by infusion could be self-administered using a subcutaneous injection.
A phase III trial examining the use of Herceptin is currently being carried out.
Pat Yang, head of Roche's global technical operations, stated: "This innovative formulation and the associated new device are designed to simplify patients' lives. There is also hope that patients will experience fewer infusion reactions due to the slower absorption."
Last week, Roche revealed that the Food and Drug Administration has approved its rheumatoid arthritis therapy ACTEMRA (tocilizumab).Other news stories from 20/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
